Lauren Ziemba
Research Subjects
Research Interests
Lauren Ziemba has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Wiznia
National Institutes of Health , Bethesda, Md
1 shared publication Ann M Buchanan
ViiV Healthcare , Durham, NC
1 shared publicationCynthia Brothers
ViiV Healthcare , Durham, NC
1 shared publicationHelena Rabie
Department of Pediatrics and Child Health, Stellenbosch University , Cape Town
1 shared publicationLionel K Tan
ViiV Healthcare , London
1 shared publicationMarcia Wang
GSK , Collegeville, PA
1 shared publication
Latest Publications
- Open Access
- 12 September 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (10)
Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019
Background: We evaluated growth outcomes in children and adolescents with HIV-1 initiating or switching to dolutegravir-based antiretroviral therapy (ART) in the single-arm International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network studies P1093 and IMPAACT 2019. Methods: We performed descriptive post hoc analyses of body mass index–for-age (BAZ), weight-for-age (WAZ), and length/height-for-age z scores (L/HAZ) for each trial through Week 48. Changes in BAZ were assessed using a mixed model for repeated measures. Results: We included data from 181 and 57 participants from P1093 and IMPAACT 2019, respectively (10% [23/238] were adolescents). Baseline mean BAZ was −0.1 in P1093 and −0.7 in IMPAACT 2019. At Week 48, adjusted mean BAZ increased significantly in P1093 (0.3; 95% CI, 0.03, 0.49; P < .05) and non-significantly in IMPAACT 2019 (0.3; 95% CI, −0.03, 0.58; P = .074). Mean BAZ was in the normal range at Week 48 in both trials. Marked increases in BAZ were observed among subgroups with baseline BAZ <−2. By Week 48, 65% (117/181) of participants in P1093 and 74% (42/57) in IMPAACT 2019 remained in the same BAZ category. Improvements from severe or moderate malnutrition/thinness to normal weight occurred in 6% (10/181) and 7% (4/57) of participants in P1093 and IMPAACT 2019, respectively, while increases to overweight or obesity were observed in 9% (16/181) and 5% (3/57). Small changes were observed in overall mean WAZ and L/HAZ through Week 48 in both trials. Conclusion: Small overall increases in BAZ were observed over 1 year among pediatric participants on dolutegravir-based ART, with most participants remaining in their baseline BAZ category. Clinical trial information: ClinicalTrials.gov, NCT01302847 and NCT03760458.
- 12 September 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (10)
Open AccessGrowth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019
Background: We evaluated growth outcomes in children and adolescents with HIV-1 initiating or switching to dolutegravir-based antiretroviral therapy (ART) in the single-arm International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network studies P1093 and IMPAACT 2019. Methods: We performed descriptive post hoc analyses of body mass index–for-age (BAZ), weight-for-age (WAZ), and length/height-for-age z scores (L/HAZ) for each trial through Week 48. Changes in BAZ were assessed using a mixed model for repeated measures. Results: We included data from 181 and 57 participants from P1093 and IMPAACT 2019, respectively (10% [23/238] were adolescents). Baseline mean BAZ was −0.1 in P1093 and −0.7 in IMPAACT 2019. At Week 48, adjusted mean BAZ increased significantly in P1093 (0.3; 95% CI, 0.03, 0.49; P < .05) and non-significantly in IMPAACT 2019 (0.3; 95% CI, −0.03, 0.58; P = .074). Mean BAZ was in the normal range at Week 48 in both trials. Marked increases in BAZ were observed among subgroups with baseline BAZ <−2. By Week 48, 65% (117/181) of participants in P1093 and 74% (42/57) in IMPAACT 2019 remained in the same BAZ category. Improvements from severe or moderate malnutrition/thinness to normal weight occurred in 6% (10/181) and 7% (4/57) of participants in P1093 and IMPAACT 2019, respectively, while increases to overweight or obesity were observed in 9% (16/181) and 5% (3/57). Small changes were observed in overall mean WAZ and L/HAZ through Week 48 in both trials. Conclusion: Small overall increases in BAZ were observed over 1 year among pediatric participants on dolutegravir-based ART, with most participants remaining in their baseline BAZ category. Clinical trial information: ClinicalTrials.gov, NCT01302847 and NCT03760458.